Doximity, Inc. $DOCS Stock Holdings Lifted by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. increased its holdings in Doximity, Inc. (NYSE:DOCS) by 526.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 179,400 shares of the company’s stock after purchasing an additional 150,755 shares during the quarter. Jefferies Financial Group Inc. owned 0.10% of Doximity worth $5,084,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. Carmignac Gestion boosted its position in Doximity by 127.8% during the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock valued at $100,480,000 after buying an additional 2,418,971 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Doximity in the 3rd quarter valued at approximately $28,858,000. Renaissance Technologies LLC boosted its holdings in shares of Doximity by 29.4% during the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock valued at $71,292,000 after buying an additional 694,300 shares in the last quarter. Wellington Management Group LLP boosted its stake in Doximity by 24.7% during the second quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock worth $65,022,000 after acquiring an additional 621,464 shares in the last quarter. Finally, Amundi grew its stake in shares of Doximity by 9,956.5% in the 1st quarter. Amundi now owns 569,095 shares of the company’s stock worth $13,260,000 after buying an additional 563,436 shares during the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Insider Buying and Selling

In related news, CAO Siddharth Sitaram sold 2,613 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $30.68, for a total value of $80,166.84. Following the completion of the sale, the chief accounting officer directly owned 101,432 shares in the company, valued at $3,111,933.76. This trade represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy Cabral sold 10,721 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $375,235.00. Following the completion of the sale, the director directly owned 8,084 shares in the company, valued at approximately $282,940. This represents a 57.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 22,701 shares of company stock worth $717,401. 31.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DOCS has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on Doximity from $26.00 to $31.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Royal Bank Of Canada lifted their price objective on Doximity from $28.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, November 6th. Truist Financial upped their target price on shares of Doximity from $19.00 to $24.00 and gave the company a “hold” rating in a report on Thursday, August 13th. Evercore set a $35.00 price objective on Doximity in a research note on Tuesday, September 29th. Finally, Stifel Nicolaus set a $27.00 price objective on Doximity in a research report on Tuesday, September 8th. Eight investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $30.59.

Latest Doximity News

Here’s some of the latest news about DOCS:

• Positive Sentiment: Doximity reportedly rolled out DoseCheck, a medication-dosing tool, following a period of near-zero drug-dosing errors. The product could support its offerings for healthcare professionals, though the article provides limited detail on its commercial impact. Doximity rolls out DoseCheck
• Neutral Sentiment: Barclays raised its DOCS price target to $30 from $27 while maintaining an “equal weight” rating. The higher target is a modest positive revision, but remains below the $33.28 share price cited in the provided background. Barclays sets a new price target
• Negative Sentiment: Several law firms publicized a securities class action covering investors who bought DOCS shares from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about engagement, competitive share and revenue expectations, including allegedly lowering and then missing fiscal 2026 guidance. The repeated announcements may renew concern about legal and reputational risk; the allegations remain unproven. Class action deadline and allegations

Doximity Trading Up 0.2%

Shares of Doximity stock opened at $33.28 on Friday. The stock has a 50 day moving average of $29.61 and a 200 day moving average of $25.36. Doximity, Inc. has a 12 month low of $17.15 and a 12 month high of $51.85. The firm has a market cap of $5.93 billion, a PE ratio of 46.22, a PEG ratio of 34.61 and a beta of 1.29.

Doximity (NYSE:DOCS) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.17. Doximity had a net margin of 21.12% and a return on equity of 15.80%. The company had revenue of $174.54 million for the quarter. During the same quarter in the prior year, the firm posted $0.45 EPS. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. As a group, equities research analysts forecast that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.

Doximity Profile

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.